Population
Patients with coronary artery disease, especially those with extensive and diffuse disease
Design
Review
Authors
Loading...
Supports CABG role amid PCI competition; leaves open which minimally invasive innovations improve outcomes in trials.
Despite increasing competition from percutaneous interventions, CABG remains a durable treatment for extensive coronary artery disease, supported by evolving minimally invasive techniques.
Sellke et al. (2010) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: